By the Numbers: The National Health Insurance Market in 2020

The year 2020 has been filled with unpredictability amid all the changes ushered in by the COVID-19 pandemic. Because of the pandemic-driven economic crisis and ballooning unemployment, member enrollment has seen significant shifts from commercial health coverage toward managed Medicaid plans, according to AIS’s Directory of Health Plans. Though insurers are required to cover coronavirus testing and many chose to waive out-of-pocket costs for coronavirus treatment, their gross margins soared compared to 2019 as a result of significant drops in elective and routine care utilization.

NOTES: Per AIS’s research methodology, Medicare Advantage membership include lives enrolled in Medicare Advantage plans, dual-eligible special needs plans and CMS’s Financial Alignment Initiative demonstration plans for Medicare-Medicaid dual eligibles.

SOURCES: AIS’s Directory of Health Plans, as of December 2020 and 2019. Managed Markets Insight & Technology, LLC, as of October 2020. “Health Insurer Financial Performance Through September 2020,” Kaiser Family Foundation. Visit https://bit.ly/37GYz3K.

© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.

Related Posts

handshake
December 5

Warranties Can Help Mitigate Risk for Payers, Manufacturers Alike

Read More
businessman-analyzing-company-report-working-with-digital-augmented-reality-graphics
December 5

MMIT Payer Portrait: Intermountain’s Select Health

Read More
old-man-touching-eye
December 5

Even at 10% Discount, Eylea Biosimilar Pavblu Offers Lower-Cost Option

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today